Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, Durkalski V, Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Smith A, Brown R, Crippin J, Harrison ME, Koch D, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hassanein T, Hanje AJ, Olson J, Subramanian R, Karvellas C, Hameed B, Sherker AH, Robuck P, Lee WM
It functions as both a GIP and GLP-1 receptor agonist
Diabetes Technology & Therapeutics, 25(2), 117-126
Five participants withdrew from the trial, including four in the placebo arm (two participants did not provide a reason for withdrawal, one participant did not have a weight loss response, and the remaining participant withdrew due to adverse event (AE) reasons)
doi: 10.1016/0165-1781(95)02656-h 191